Cervical Cancer

Advaxis' Phase II Clinical Trial "HOLD" Lifted
Advaxis Inc (OTCBB: ADXS), a biotechnology company, received permission from the U. S. Food and Drug Administration (FDA) to test its lead drug candidate, Lovaxin C, in patients with grade 2/3 cervical intraepithelial neoplasia (CIN). With this approval of the Investigational New Drug (IND) application for Lovaxin C, the FDA "HOLD" on Advaxis' clinical program has been lifted.